This roundtable series explores immune checkpoint inhibitors and combination therapy for patients with unresectable or metastatic hepatocellular carcinoma in the frontline setting, as discussed by key opinion leaders at virtual live events and interviews.

Treating First-Line HCC With Immune Checkpoint Inhibition

Analyzing Nivolumab and Ipilimumab as HCC Therapy

November 11, 2025

During a live event, Anthony B. El-Khoueiry, MD, discussed nivolumab plus ipilimumab vs lenvatinib/sorafenib in unresectable HCC.

Diagnosis and Management of Unresectable HCC Using Clinical Criteria

October 23, 2025

During a live event, Anthony B. El-Khoueiry, MD, discussed downstaging for transplant and evolving frontline systemic therapies in advanced HCC.

How to Respond to Toxicities of Each Combination HCC Regimen

July 24, 2025

During a live event, Mark Yarchoan, MD, and participants reviewed adverse event management for 3 different combination regimens for hepatocellular carcinoma.